Dong R, Liu R, Liu Z, Liu Y, Zhao G, Li H
Elife. 2025; 13.
PMID: 40079572
PMC: 11906162.
DOI: 10.7554/eLife.97330.
Fan X, Cheng Z, Shao R, Ye K, Chen X, Cai X
Clin Transl Med. 2025; 15(3):e70263.
PMID: 40045452
PMC: 11882392.
DOI: 10.1002/ctm2.70263.
Kalemati M, Zamani Emani M, Koohi S
Heliyon. 2025; 11(3):e42476.
PMID: 40007773
PMC: 11850134.
DOI: 10.1016/j.heliyon.2025.e42476.
Konate S, Allangba K, Fofana I, NGuessan R, Megnassan E, Miertus S
Life (Basel). 2025; 15(2).
PMID: 40003582
PMC: 11856008.
DOI: 10.3390/life15020173.
Syngkli S, Singh S, Rani R, Das B
Protein J. 2025; .
PMID: 39987391
DOI: 10.1007/s10930-025-10252-1.
Harnessing pre-trained models for accurate prediction of protein-ligand binding affinity.
Li J, Gong X
BMC Bioinformatics. 2025; 26(1):55.
PMID: 39962390
PMC: 11834573.
DOI: 10.1186/s12859-025-06064-w.
Barlow Twins deep neural network for advanced 1D drug-target interaction prediction.
Schuh M, Boldini D, Bohne A, Sieber S
J Cheminform. 2025; 17(1):18.
PMID: 39910404
PMC: 11800607.
DOI: 10.1186/s13321-025-00952-2.
The Intricate Mechanisms of Functional Foods Oyster Mushroom and Fenugreek on Type 2 Diabetic Animal Model.
Razon A, Alauddin M, Farzana N, Mazumdar S, Amin M, Tusher M
J Diabetes Res. 2025; 2024:6209785.
PMID: 39885962
PMC: 11779994.
DOI: 10.1155/jdr/6209785.
Rationalizing protein-ligand interactions via the effective fragment potential method and structural data from classical molecular dynamics.
Urbina A, Slipchenko L
J Chem Phys. 2025; 162(4).
PMID: 39868918
PMC: 11774556.
DOI: 10.1063/5.0247878.
Virtual screening: hope, hype, and the fine line in between.
Nada H, Meanwell N, Gabr M
Expert Opin Drug Discov. 2025; 20(2):145-162.
PMID: 39862145
PMC: 11844436.
DOI: 10.1080/17460441.2025.2458666.
Discovery of highly potent phosphodiesterase-1 inhibitors by a combined-structure free energy perturbation approach.
Li Z, Jiang M, Liu R, Wang Q, Zhou Q, Huang Y
Acta Pharm Sin B. 2025; 14(12):5357-5369.
PMID: 39807312
PMC: 11725145.
DOI: 10.1016/j.apsb.2024.06.021.
MRPL24 drives breast cancer metastasis and stemness by targeting c-MYC, BRD4, and STAT3.
Khan A, Khan I, Man S, Liu S, Ailun G, Abbas M
3 Biotech. 2025; 15(2):37.
PMID: 39802327
PMC: 11718041.
DOI: 10.1007/s13205-024-04196-z.
Evaluation of H1-Antihistamine as Potential Inhibitors of SARS-CoV-2 RNA-dependent RNA Polymerase: Repurposing Study of COVID-19 Therapy.
Hamdan M, Kulabas N, Kucukguzel I
Turk J Pharm Sci. 2025; 21(6):566-576.
PMID: 39801109
PMC: 11730003.
DOI: 10.4274/tjps.galenos.2024.49768.
Jaranol alleviates cognitive impairment in db/db mice through the PI3K/AKT pathway.
Qian Y, Xu Y, Zhang Q, Huang C, Li H, Gao L
Metab Brain Dis. 2025; 40(1):88.
PMID: 39760807
DOI: 10.1007/s11011-024-01527-0.
Comparison of new secondgeneration H1 receptor blockers with some molecules; a study involving DFT, molecular docking, ADMET, biological target and activity.
Unsal V, Oner E, Yildiz R, Mert B
BMC Chem. 2025; 19(1):4.
PMID: 39755645
PMC: 11700471.
DOI: 10.1186/s13065-024-01371-4.
MM-DRPNet: A multimodal dynamic radial partitioning network for enhanced protein-ligand binding affinity prediction.
Liu D, Song T, Wang S
Comput Struct Biotechnol J. 2024; 23:4396-4405.
PMID: 39737077
PMC: 11683220.
DOI: 10.1016/j.csbj.2024.11.050.
Gallic Acid: A Potent Metabolite Targeting Shikimate Kinase in .
Alturki M, Al Khzem A, Gomaa M, Tawfeeq N, Alhamadah M, Alshehri F
Metabolites. 2024; 14(12).
PMID: 39728508
PMC: 11677302.
DOI: 10.3390/metabo14120727.
Efficacy and safety of TACE combined with traditional Chinese medicine versus TACE alone in hepatocellular carcinoma: bayesian network meta-analysis and pharmacological mechanisms study.
Chen L, Zhu X, Lin J, Li D
Front Pharmacol. 2024; 15:1495343.
PMID: 39712495
PMC: 11662279.
DOI: 10.3389/fphar.2024.1495343.
Molecular modeling, synthesis and biological evaluation of caffeic acid based Dihydrofolate reductase inhibitors.
Sehrawat R, Pasrija R, Rathee P, Kumari D, Khatkar A
BMC Chem. 2024; 18(1):242.
PMID: 39696655
PMC: 11658390.
DOI: 10.1186/s13065-024-01355-4.
Identification of dimethyl 2,2'-((methylenebis(2-(2H-benzo[d][1,2,3]triazol-2-yl)-4-(2,4,4-trimethylpentan-2-yl)-6,1phenylene))bis(oxy))diacetate (TAJ4) as antagonist of NEK-Family: a future for potential drug discovery.
Aziz M, Ejaz S, Ali Channar P, Alkhathami A, Qadri T, Hussain Z
BMC Cancer. 2024; 24(1):1521.
PMID: 39696038
PMC: 11658429.
DOI: 10.1186/s12885-024-13269-4.